In four of them (25%), they identified a novel antibody targeting RNPC-3 (a protein of the minor spliceosome) [27].Thus, the concept of “dnANA” or “CTP-negative” patients, could be more appropriate to refer to a subgroup of patients with yet-undiscovered autoantibodies cross-reacting with tumor antigens and at risk of cancer within a short time of SSc diagnosis [27]. This evidence concerns the gene RNPC3 and cancer.